Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer's-related psychosis during the ...

A recent study has linked thyroid and liver proteins, transthyretin (TTR) and apolipoprotein A-I (ApoA-I), to brain health, ...

Researchers at Nanyang Technological University in Singapore have identified a new “energy switch” in immune cells of the ...

Researchers have discovered that suppressing a nucleolar complex can reduce Alzheimer’s-related protein toxicity. Scientists ...

The agreement with China Medical System Holdings Limited is for the development, manufacturing, and commercialization of ...

Use of the treatment has soared in popularity in recent years now taken by 2.6million women in England according to the ...

Company to Present Breakthrough Research Approach for a New Generation of Neurodegenerative Therapeutics GAINESVILLE, Fla., ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

Medical advances make pills to treat Alzheimer’s disease viable, though challenges remain in sharing gains globally ...

Their Phase 2a clinical trial of Hoth's topical gel HT-001 has shown 100% success in combating skin toxicities caused by ...

For years, researchers have debated the root cause of Alzheimer’s. Two main theories dominate the discussion. The first ...